Trial Profile

A multi-centre, double-blind, randomised-withdrawal, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR (TM)) as monotherapy in the maintenance treatment of patients with major depressive disorder.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Jul 2012 Results published in the International Clinical Psychopharmacology.
16 Sep 2009 Results of a secondary analysis investigating the effects of quetiapine on functioning and sleep quality have been presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology.
03 May 2008 Results have been presented at the 161st Annual Meeting of the American Psychiatric Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com